Enovix Q3 revenue $0.2M; cash $371.3M; narrows FY2023 cash use guidance to $110M

Enovix Corp

2023-Q3 EPS reported -$1.00 revenue$263,000

Q3 revenue $0.2M from U.S. Army cells; GAAP cost of revenue $16.8M; GAAP op. expenses $33.8M.
Cash, equivalents, and short-term investments $371.3M; Q3 operating cash use $28.2M; capex $17.3M.
FY2023 operational cash use forecast lowered to $110M (from $120M); capex to $65M (from $70M).
Completed FAT for one Gen2 production zone; expects all four zones FAT by Jan 2024; first samples by Apr 2024.
Acquired Routejade for electrode coating; Fab1 restructuring reduces annualized cash burn ~$22M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Enovix Corp reported financial results for third fiscal quarter ended October 1, 2023.

Period: third fiscal quarter ended October 1, 2023
Result: reported results

Exact text from the filing

On November 7, 2023, Enovix Corporation issued a press release announcing the release of its financial results for the third fiscal quarter ended October 1, 2023.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

Enovix Corp filing history →

Source: SEC EDGAR

accession 0001828318-23-000202

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.